Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 105,250,712
  • Shares Outstanding, K 1,639,930
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.19
  • Price/Sales 5.37
  • Price/Cash Flow 20.73
  • Price/Book 7.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.27 +3.07%
on 09/18/17
66.10 -2.90%
on 10/13/17
+1.70 (+2.72%)
since 09/15/17
3-Month
52.06 +23.28%
on 07/27/17
66.10 -2.90%
on 10/13/17
+9.39 (+17.14%)
since 07/17/17
52-Week
46.01 +39.49%
on 01/26/17
66.10 -2.90%
on 10/13/17
+14.84 (+30.08%)
since 10/17/16

Most Recent Stories

More News
Bristol-Myers Gets Priority Review for Opdivo Label Expansion

Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

AZN : 34.78 (+0.38%)
NVO : 49.31 (-0.02%)
MRK : 63.22 (-0.19%)
BMY : 64.18 (+0.83%)
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

EXEL : 28.30 (-2.48%)
RHHBY : 31.4500 (+0.87%)
GSK : 40.83 (-0.07%)
BMY : 64.18 (+0.83%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review

--Application based on results from Phase 3 CheckMate -238 study

BMY : 64.18 (+0.83%)
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

The pharma/biotech sector has a number of things going in its favor.

AZN : 34.78 (+0.38%)
LLY : 86.06 (+0.13%)
PFE : 36.20 (+0.61%)
GSK : 40.83 (-0.07%)
BMY : 64.18 (+0.83%)
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.

NVS : 86.34 (-0.03%)
GILD : 80.24 (+0.36%)
ICPT : 67.06 (-0.46%)
BMY : 64.18 (+0.83%)
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

AERI : 64.60 (+0.86%)
ACRX : 1.75 (-10.26%)
MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
AGN : 197.78 (-0.32%)
PFE : 36.20 (+0.61%)
BMY : 64.18 (+0.83%)
Non-Alcoholic Steatohepatitis 2017 Progress Update

Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

CNAT : 5.10 (-4.14%)
AGN : 197.78 (-0.32%)
NVS : 86.34 (-0.03%)
GILD : 80.24 (+0.36%)
ICPT : 67.06 (-0.46%)
BMY : 64.18 (+0.83%)
Seattle Genetics Inks Clinical Collaborations for Cancer Drug

Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.

MRK : 63.22 (-0.19%)
INFI : 2.70 (-8.47%)
SGEN : 64.08 (+1.89%)
BMY : 64.18 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 64.95
1st Resistance Point 64.56
Last Price 64.18
1st Support Level 63.60
2nd Support Level 63.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart